• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Teva Announces Philadelphia-Area Layoffs

americanpharmaceuticacreviewJanuary 23, 2018

Tag: Teva Announces , layoffs , Generic

Teva Pharmaceuticals will lay off 208 people this year at their Pennsylvania-based locations, according to notices filed with the Pennsylvania Department of Labor and Industry.

The Israeli generic drug maker, which has its U.S. headquarters located in North Wales, Pa., announced at the end of 2017 it would eliminate 14,000 positions globally over the next two years.

The company notified state regulators that it will cut 65 jobs at two locations in North Wales and Horsham, 47 jobs in West Chester, and 96 jobs in Frazer and Great Valley. The notices were listed as layoffs, scheduled to take place by the end of 2018.

Previous:New Player Joining, what will be Its Odds of Success in Marching into the Hypoglycemic Drug Market?

Next:Group Health Cooperative Eau Claire Partners with Valera in Innovative Behavioral Health Management

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Teva Announces Philadelphia-Area Layoffs | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Generic Soft Mist Inhaler

Generic Soft Mist Inhaler
Generic Diskus

Generic Diskus
20mm crimp on nasal pump, Dosed, Generic to, AB rated

20mm crimp on nasal pump, Dosed, Generic to, AB rated
Generic Breezhaler

Generic Breezhaler
Nasal pump for Generics

Nasal pump for Generics
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service